SUMMARY

Objective: Evaluate the seizure-reduction response and safety of mesial temporal lobe (MTL) brain-responsive stimulation in adults with medically intractable partial-onset seizures of mesial temporal lobe origin.

Methods: Subjects with mesial temporal lobe epilepsy (MTLE) were identified from prospective clinical trials of a brain-responsive neurostimulator (RNS System, NeuroPace). The seizure reduction over years 2–6 postimplantation was calculated by assessing the seizure frequency compared to a preimplantation baseline. Safety was assessed based on reported adverse events.

Results: There were 111 subjects with MTLE; 72% of subjects had bilateral MTL onsets and 28% had unilateral onsets. Subjects had one to four leads placed; only two leads could be connected to the device. Seventy-six subjects had depth leads only, 29 had both depth and strip leads, and 6 had only strip leads. The mean follow-up was 6.1 (standard deviation 2.2) years. The median percent seizure reduction was 70% (last observation carried forward). Twenty-nine percent of subjects experienced at least one seizure-free period of 6 months or longer, and 15% experienced at least one seizure-free period of 1 year or longer. There was no difference in seizure reduction in subjects with and without mesial temporal sclerosis (MTS), bilateral MTL onsets, prior resection, prior intracranial monitoring, and prior vagus nerve stimulation. In addition, seizure reduction was not dependent on the location of depth leads relative to the hippocampus. The most frequent serious device-related adverse event was soft tissue implant-site infection (overall rate, including events categorized as device-related, uncertain, or not device-related: 0.03 per implant year, which is not greater than with other neurostimulation devices).

Significance: Brain-responsive stimulation represents a safe and effective treatment option for patients with medically intractable epilepsy, including patients with unilateral or bilateral MTLE who are not candidates for temporal lobectomy or who have failed a prior MTL resection.

KEY WORDS: Closed-loop, Neuromodulation, Partial seizures, Hippocampus, Focal stimulation.
Temporal lobectomy is the most effective treatment for many patients with medically intractable mesial temporal lobe epilepsy (MTLE). However, 25–35% of patients with MTLE who are treated with resective or ablative surgeries do not achieve sustained seizure freedom, and others are not candidates for surgery because the risks, particularly to memory or language, are too high.\(^1\)–\(^5\) Neuromodulation therapies are a treatment option for some of these patients.

Brain-responsive (closed-loop) neurostimulation (RNS System) is a safe and effective adjunctive treatment to reduce the frequency of seizures in medically refractory adults with partial-onset seizures.\(^6\)–\(^8\) However, the results specific to subjects with MTLE have not been published previously.

This report provides an analysis of the long-term results of responsive MTLE stimulation in subjects with MTLE participating in the RNS System clinical trials. This experience may assist physicians when counseling patients who are considering or being treated with brain-responsive stimulation.
SUBJECTS

Subjects with MTLE who participated in clinical trials of the RNS System were included in the analyses. Study protocols were approved by the institutional review boards of participating investigation sites. All subjects provided written informed consent. The studies were registered on www.clinicaltrials.gov (NCT00079781, NCT00264810, and NCT00572195).

Long-term seizure reduction

Long-term results over years 2–6 postimplantation were measured as median percent change in seizures and responder rate (the percentage of subjects with a 50% or greater reduction in seizures) for each 3-month period compared to the preimplantation baseline. Seizure data were collected using seizure diaries.

In addition, last observation carried forward (LOCF) analyses based on the most recent 3 months of available open-label seizure diary data for each subject were performed. This ensured that the results were not influenced by subjects who discontinued or those who had not yet completed 6 years of follow-up.

Long-term seizure reduction by demographic characteristics

Seizure reduction was compared for subjects with bilateral and unilateral MTL seizure onsets, and according to prespecified characteristics that could potentially affect the clinical response to treatment. These included whether the subject had mesial temporal sclerosis (MTS), had intracranial monitoring for localization, or had been treated with vagus nerve stimulation (VNS) or temporal lobectomy. A logistic generalized estimating equation (GEE) model was fit to the results for mean percent change for each 3-month period from the beginning of year 2 through the end of year 6 for each of the comparisons. GEE is an extension of generalized linear modeling that handles missing data and properly assigns significance to multiple correlated measurements. The percent change in seizure rate for all available 3-month epochs was analyzed using a GEE model with a compound symmetric correlation structure.9 p-Values were based on empirical standard errors. For all comparisons, α was set to p < 0.05. In addition, median percent change and responder rate using LOCF were calculated for each clinical characteristic.

Depth lead placement

Depth lead location relative to the hippocampus was determined for subjects with preimplantation magnetic resonance imaging (MRI) and postimplantation computed tomography (CT) coregistered images. The coregistered images were reviewed by two independent neurosurgeons who categorized a depth lead as within the hippocampus if at least two of the four electrode contacts were in the hippocampus, and outside of the hippocampus if more than two of the four contacts were not in the hippocampus. Seizure reduction was assessed using the GEE and LOCF analysis methods described earlier.

Long-term Safety

Safety was assessed as the rate and types of spontaneously reported serious and mild adverse events (AEs)8 and classified by the investigator as device related (definitely or potentially related to the RNS System) or not. An independent Data Monitoring Committee reviewed all AEs and a second committee determined whether deaths met criteria for sudden unexpected death in epilepsy (SUDEP).

RESULTS

There were 111 subjects with MTLE treated with responsive stimulation during the Feasibility (N = 16) and Pivotal (N = 95) studies, and 102 subjects continued into the LTT study. Subject accountability and reasons for discontinuation are provided in Figure 1. The mean follow-up at the time of data cutoff was 6.1 ± (standard deviation) 2.2 years, and the accumulated experience was 671 patient implant years and 631 patient years during which responsive MTL stimulation was provided.

Demographic characteristics

Demographic characteristics are provided in Table 1. Most subjects had frequent seizures for many years and had failed treatment with multiple antiepileptic medications and in some cases VNS (24%) or temporal lobectomy (12%). MTS was present in 55% of subjects. Ictal onsets were bilateral in 72% of subjects and unilateral in 28% (68% left; 32% right). Sixty percent of subjects with unilateral right onsets had undergone a temporal lobectomy (three right; three left).

Lead placement approaches

Subjects had one to four leads placed during the initial procedure: one lead (n = 1); two leads (n = 92); three leads (n = 4); and four leads (n = 14). Only two depth leads could be implanted and only two leads of any type could be connected to the device at a time. Seventy-six subjects had only depth leads placed, 29 had both depth and strip leads, and 6 had only strip leads. Most depth leads were implanted along the longitudinal axis of the hippocampus. Cortical strip leads were typically placed subtemporally. CT scans showing common lead implantation strategies are provided in Figure 2(A–C).

Of the 13 subjects with a prior temporal lobectomy, leads were contralateral (n = 6), ipsilateral (n = 2), or both (n = 5) to the resection. All subjects had at least one depth lead.
Sixty-two of the subjects had coregistered MRI and CT images with sufficient resolution for localizing the depth leads. In 31 subjects, at least one depth lead was positioned in the hippocampus. The remaining 31 subjects had depth leads near but not within the hippocampus. Figure 2(D–E) shows bilateral depth lead placements in two subjects; one with leads within the hippocampus and one with leads ventral to the hippocampus.

Figure 3 shows representative ECoG recordings from MTLE subjects. Stimulation was commonly delivered to hypersynchronous and low-voltage fast electrographic activity. Typical stimulation settings were: 1.5–2.5 μC/cm² (range 0.1–19.0 μC/cm²); 1.0–3.0 mA (range 0.5–12.0 mA); 200 Hz (range 1–333 Hz); 160 μsec pulse width (range 80–1000 μsec); and 100 msec burst duration (range 10–5,000 msec). The median number of programming changes from the beginning of the second-year postimplantation to the end of the data analysis period was 3 per year per subject (range 1–7). These programming changes included adjustments to stimulation, detection, or both.

**Long-term seizure reduction**

The long-term response to treatment with MTL responsive stimulation is presented in Figure 4. Disabling seizures were reduced by a median 66.5% (interquartile range [IQR] 31.8–93.7%) at 6 years, and the 50% responder rate reached 64.6% (95% confidence interval [CI] 53.8–74.1%). Using LOCF, disabling seizures were reduced by a median of 70% (IQR 31.8–92.9%; n = 106), and the responder rate was 66% (95% CI 56.6–74.4%). No seizures were reported by 20.8% of subjects in the last 3 months. Over the entire open-label period, 45% (50/111) of subjects reported seizure-free intervals lasting ≥3 months, 29% ≥6 months (32/111), and 15% ≥1 year (17/111).

There were no statistically significant differences, by GEE, in seizure reduction between subjects with and without MTS (p = 0.42), between subjects with bilateral and
unilateral onsets (p = 0.97), between subjects localized with intracranial monitoring and those not (p = 0.15), and between those treated and not treated previously with VNS (p = 0.78) or epilepsy surgery (p = 0.54). Table 2 provides the median percent change and responder rates using an LOCF analysis for each of the demographic characteristics.

In addition, there were no statistically significant differences in seizure reduction between subjects with at least one depth lead in the hippocampus and subjects with depth leads outside of the hippocampus (GEE, p = 0.9). The LOCF median percent reduction in seizure rate was 77.8% (IQR 32.3–100%; n = 31) for the hippocampal group and 60.2% (IQR 29.9–87.8%; n = 31) for the MTL extra-hippocampal group. The LOCF responder rates were 67.7% (95% CI 50.1–81.4%) and 61.3% (95% CI 43.8–76.3%), respectively.

**Device-related serious adverse events**

There were only two device-related (related or uncertain as categorized by the investigator) serious adverse events (SAEs) that occurred in ≥5% of the 111 subjects over the 671 patient implant years. The SAEs were implant-site infection and device lead damage, described in detail in subsequent text.
Implant-site infection

There were 15 SAEs (device-related or uncertain) occurring in 13 subjects (11.7%). All infections were superficial soft tissue only and there were no long-lasting neurologic or medical consequences. The implant-site infections occurred during the immediate postoperative period for three of the subjects; one had the neurostimulator and leads explanted. For the remaining subjects, the implant-site infection occurred beyond the immediate postoperative period; seven occurred within 3 months of a neurostimulator replacement. All subjects were treated with antibiotics; nine had their neurostimulator explanted, and six were later reimplanted.

In addition, two subjects experienced implant-site infections that were categorized as not device related. The infections occurred during the immediate postoperative period. Both were treated with antibiotics; one subject had the neurostimulator explanted and subsequently reimplanted.

Another two subjects experienced implant-site infections as a result of seizure-related injuries. Both subjects had their devices and leads explanted.

Finally, three SAEs related to implant-site skin erosion were reported in two subjects. Two events were reported in one subject; the events occurred over 7.5 years apart. The first event resolved with antibiotics and surgical removal of the device, and the subject was reimplanted. However, the neurostimulator was explanted and not replaced following the second event. For the second subject, the SAE resolved with antibiotics and device removal. They were reimplanted with no further complications.

The overall rate of SAEs due to infection was 0.03 per patient implant year.

Device lead damage

Seven subjects (6.3%) required lead replacement due to lead damage. The overall rate of SAEs due to lead damage was 0.01 per patient implant year.

Other adverse events of interest

Intracranial hemorrhage

Three subjects (2.7%) had a serious AE related to intracranial hemorrhage (two were categorized as device-related). One was a CT-diagnosed asymptomatic intraventricular hemorrhage within the first days after bilateral depth-lead implant. The second subject sustained a subarachnoid hemorrhage following seizure-related head trauma. Neither of these events had any neurologic consequences.
The final subject had a subtemporal hematoma 2.5 years after implantation of two depth leads and two cortical strip leads. The subject experienced headaches that subsequently resolved. In addition, one subject reported a mild AE related to a small postoperative subdural hematoma near the site of the neurostimulator and leads that resolved without intervention.

**Death**

There were 6 deaths in the 111 subjects over the 671 patient implant years and 631 patient stimulation years. One subject had a history of depression and died by suicide. Five deaths were attributed to possible (n = 2), probable (n = 1), or definite (n = 2) SUDEP; two of these occurred while brain-responsive stimulation was off. Stimulation had been disabled in the first subject for >200 days, and the second subject had not yet had stimulation enabled after the initial implant. None of the SUDEP events were deemed to be related to the device.

**Photopsia**

Transient mild AEs related to photopsia that were deemed to be related to the device or of uncertain device relation were reported in 16 subjects (14.4%). All but one event resolved spontaneously or with changes to the stimulation parameters.

**Memory impairment**

Transient mild AEs related to memory impairment that were deemed to be related to the device or of uncertain device relation were reported in seven subjects (6.3%). All of these subjects had memory impairment on preimplant baseline neuropsychological assessment.

**Depression**

Two subjects (1.8%) reported transient SAEs related to depression with suicidal ideation that were deemed to be related to the device or of uncertain device relation. Both subjects had a prior history of depression and one had a prior history of a suicide attempt. In addition, as mentioned earlier, one MTL subject committed suicide during the trial. This subject also had a prior history of depression and suicidal ideation.

Mild AEs related to depression deemed to be of uncertain device relation were also reported in four subjects (3.6%). Two of the four subjects met criteria for moderate depression at baseline by validated mood inventory (Beck Depression Inventory-II; BDI-II) and/or reported a prior medical history of depression.

**Figure 4.**

Long-term response to brain responsive stimulation in patients with MTLE. (A) Median percent change in total disabling seizures in each 3-month bin beginning in Year 2 postimplantation. Error bars indicate interquartile ranges (25th–75th). (B) Responder Rate (percent of patients with a ≥50% reduction in total disabling seizures) in each 3-month bin beginning in Year 2 post-implantation. Error bars indicate 95% confidence intervals. © 2017 NeuroPace, Inc.

Epilepsia, 58(6):994–1004, 2017
doi: 10.1111/epi.13740
Responsive Neurostimulation for MTLE

Table 2. LOCF by clinical demographic characteristic

<table>
<thead>
<tr>
<th>Covariate</th>
<th>N</th>
<th>Median % change (IQR)</th>
<th>Responder rate (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior intracranial monitoring</td>
<td>Yes</td>
<td>–74.5% (–29.2% to 95.4%)</td>
<td>66.7% (52.5% to 78.3%)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>–67.6% (–33.8% to 91%)</td>
<td>65.5% (52.7% to 76.4%)</td>
</tr>
<tr>
<td>Mesial temporal sclerosis</td>
<td>Yes</td>
<td>–60.6% (–30.5% to 89.2%)</td>
<td>60.3% (47.5% to 71.9%)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>–75.6% (–39.5% to 95.5%)</td>
<td>72.9% (59% to 83.4%)</td>
</tr>
<tr>
<td>Bilateral MTL onsets</td>
<td>Yes</td>
<td>–67.9% (–30% to 90%)</td>
<td>64.5% (53.3% to 74.3%)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>–72.5% (–37% to 95.9%)</td>
<td>70% (52.1% to 83.3%)</td>
</tr>
<tr>
<td>Prior epilepsy surgery</td>
<td>Yes</td>
<td>–72.5% (–57.4% to 93.5%)</td>
<td>91.7% (64.6% to 98.5%)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>–69.6% (–29.8% to 92.9%)</td>
<td>62.8% (52.7% to 71.9%)</td>
</tr>
<tr>
<td>Prior VNS</td>
<td>Yes</td>
<td>–56.8% (–27.5% to 81%)</td>
<td>63% (44.2% to 78.5%)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>–74.1% (–32.8% to 100%)</td>
<td>67.1% (56.1% to 76.4%)</td>
</tr>
</tbody>
</table>

IQR, Interquartile range. 25th to 75th percentile; VNS, vagus nerve stimulation.

Discussion

Brain responsive MTL stimulation is a new treatment for patients with medically intractable MTLE who are not good resection candidates. Hippocampal stimulation in patients with MTLE has shown efficacy and good tolerability in several small series.10–20 This is the first report of a large cohort of subjects treated with responsive mesial temporal stimulation.

In selected patients with medically intractable MTLE, anterior temporal lobectomy or amygdalohippocampectomy are often the procedures of choice, with long-term seizure-free rates of 60–75%.21 Ablative procedures may also be an option for some.22 However, many patients are not candidates for resective or ablative procedures. Seizures may arise from both temporal lobes or the risk to memory, language, or other neurologic functions is not acceptable. Many of the 111 subjects with medically refractory MTLE enrolled in the RNS System trials had bilateral MTL seizure onsets. Most of the subjects with unilateral onsets had seizures arising from the dominant temporal lobe and/or had already undergone a temporal lobectomy. Thus, the subjects included in the RNS System trials were not considered to be good surgical candidates.

Seizure reduction was substantial and sustained. Nearly half of the subjects experienced at least one ≥3-month period without seizures, and 15% were without seizures for 1 year or longer. Treatment with responsive stimulation achieved reductions in seizure frequency reaching 70% over 6 years of prospective follow-up. This contrasts favorably with continued medical management in refractory nonsurgical candidate patients with MTLE, where sustained reductions in seizures are not typically observed.5,23

Seizure reductions for MTLE subjects who had intracranial monitoring were similar to those for subjects who did not. The criteria by which an individual epilepsy center chose to localize the seizure focus or foci were not standardized within the clinical trials. Therefore, no comment about the optimal localization testing to identify patients who would benefit from responsive stimulation can be provided from this experience. However, intracranial monitoring was not required for subjects to achieve a good response. In fact, because it may take several weeks of chronic ambulatory monitoring to establish that a patient with MTLE has independent bilateral mesial temporal seizures,24 there is a chance that lateralization of MTLE may not be adequate within a 1- to 2-week hospitalization for EEG monitoring, even with intracranial electrodes.

There was no difference in seizure reduction between subjects with and without MTS. The lack of a significant difference in seizure reduction contrasts with earlier reports by Velasco et al.,18 in a small sample (n = 5 with MTS; n = 4 without) in which there was a greater and earlier reduction in seizures for MTLE patients with negative MRI findings. Future trials with standardized and sophisticated neuroimaging are required to better understand how neuroimaging might be used to optimize selection of patients for MTL responsive stimulation. In the short-term, however, patients with and without MTS can be considered candidates for responsive stimulation.

The experience with responsive MTL stimulation thus far suggests that leads need not be placed precisely within the hippocampus, since stimulation was as effective when MTL leads were placed within the hippocampus or nearby. Whether a larger volume of tissue activation was required for comparable seizure control when leads were outside the hippocampus was not assessed. However, these results are consistent with a smaller series in eight MTLE patients receiving hippocampal stimulation.11 Decreases in epileptogenic activity were related to proximity of the active electrode(s) to the subiculum and not associated with the proximity of the active electrode(s) to the ictal focus. Future research will explore whether stimulation should be delivered directly to the seizure focus, near the focus, or in relevant propagation pathways or networks and will evaluate what volume of tissue activation may be required for each stimulation target. In addition, future research will also evaluate whether other techniques such as tractography or
intraoperative electrocorticography could provide insight into the ideal lead placement for an individual patient. Responsive MTL stimulation was equally effective in subjects with bilateral or unilateral seizure onsets. There has been another report of successful treatment of bilateral as well as unilateral MTL seizures with direct brain stimulation. This series also suggested that some patients with unilateral onsets who do not respond to unilateral MTL stimulation may improve when stimulation is provided bilaterally. About one fourth of the MTLE subjects participating in the RNS System trials were previously treated with VNS. These subjects were as likely to benefit from responsive stimulation as the subjects who had not been treated with VNS. The mechanisms by which VNS and direct brain stimulation act to improve seizure control, while not completely understood, are likely quite different, suggesting that a failure to respond to one does not predict response to the other.

Some patients who have not achieved seizure control after temporal lobe resection may also be candidates for responsive MTL stimulation. Seizure reductions with responsive MTL stimulation in the RNS System trials were similar in both subjects who had and had not already undergone a MTL resection. However, it should be noted that the number of subjects with a prior resection was small, reducing the power of statistical comparisons. Some of the subjects with a prior temporal lobectomy were treated with responsive MTL stimulation ipsilateral to the resection with leads placed in residual MTL structures or at the margin of the resection; some were treated with MTL stimulation contralateral to the resection, and some were treated bilaterally. These findings suggest that responsive stimulation is an option if not all of the epileptogenic cortex can be resected. Furthermore, several case reports suggest that resective surgery and responsive stimulation can sometimes be used synergistically. Chronic ambulatory ECoG data collected by the RNS System has been used to identify patients in whom temporal resections would achieve seizure remission or substantial palliation. In some of these patients, responsive MTL stimulation was provided to the contralateral MTL.

There are limitations to the analyses of the data provided. First the trials were not powered to provide assessments in subsets of subjects. Thus, more data will be necessary to confirm the comparisons of seizure reduction by clinical demographic characteristic. Second, the identification of subjects as having MTS was based on physician report and not a standardized imaging protocol. Furthermore, because subjects with MTS can have negative MRI findings and positive histopathology, some subjects with MTS may not have been identified. Finally, the data were collected as part of an open-label study and thus the effect of antiepileptic treatments cannot be clearly defined. However, analysis of seizure reduction in the trials indicated that there was no difference in seizure response between subjects whose antiepileptic drugs (AEDs) remained stable and subjects who had AED modification.

Surgical risks related to implantation of the RNS Neurostimulator and leads were well within the expected range for comparable procedures such as intracranial monitoring for localization of the seizure focus, and deep brain stimulation for treatment of movement disorders or epilepsy. The most common device-related SAEs were implant-site infections, all of which were superficial soft tissue. The overall risk for an SAE related to infection per patient implant year was low. Perioperative hemorrhages occurred in 1.8% of subjects and were asymptomatic or caused only transient symptoms.

Long-term responsive MTL stimulation was cognitively and affectively well tolerated in these subjects with medically intractable MTLE, despite the high prevalence of moderate depression and suicidality at baseline. Meador et al. reported that 19.4% of the MTLE subjects in the Pivotal study (n = 95) met criteria for moderate depression at baseline and 10.8% endorsed suicidality. These rates did not increase with treatment; the rates of depression and suicidality at 2 years were 16% and 12.6%, respectively.

Across all 111 subjects (>671 implant years), device-related or device relation uncertain AEs related to memory were reported in 6.3%; however, all of these subjects had a preexisting memory impairment at baseline based on neuropsychological testing. Neuropsychological testing in the RNS System trials indicated that 56.8% of the Pivotal trial subjects (n = 95) had significant impairment in memory at baseline. Loring et al. reported that there were no cognitive declines with responsive MTL stimulation and that there were improvements in verbal memory, which, although small in magnitude, were statistically significant. A number of studies of open-loop hippocampal stimulation for temporal lobe epilepsy also found no adverse effects on memory.

The memory-sparing effects of MTL stimulation compare favorably to the progressive memory declines in patients with refractory MTLE who continue to be treated with AEDs. This also contrasts with cognitive outcomes following temporal lobectomy. Weighted estimates indicate a risk to verbal memory with left-sided temporal resection of 44%, and 20% for rightsided surgery. Of course, risks to memory are weighed against the high likelihood of obtaining seizure freedom following temporal lobectomy.

During the Pivotal trial, the MTLE subjects treated with responsive stimulation reported sustained improvements in overall quality of life. At 2 years of treatment, there were clinically meaningful improvements in overall quality of life (QoL) in 41% of subjects, with only 16% reporting declines. There were also significant improvements in epilepsy targeted and cognitive domains of QoL. The magnitude of improvement in QoL was less than that reported after mesial temporal lobectomy resulting in seizure remission but greater than that reported with continued medical
management. Because the subjects with MTLE in the RNS System trials were not considered candidates for temporal lobectomy, treatment with responsive MTL stimulation resulted in improvements in QoL that would not have otherwise been possible.

In conclusion, brain-responsive stimulation is a well-tolerated and reversible approach to treating MTLE. Medically refractory patients with MTLE have sustained reductions in the frequency of clinical seizures that reach 70%. The response is independent of past epilepsy treatments, and seizure reduction is achieved whether leads are placed within or close to the hippocampus. There are no stimulation-associated sustained AEs on mood or cognition, and some subjects experience memory improvement. Although responsive stimulation should be considered palliative, many subjects experience prolonged periods without seizures. Future clinical studies and additional experience with a variety of stimulation approaches should refine and further improve the response to treatment. The current clinical experience indicates that responsive stimulation offers a much-needed treatment option for patients with medically intractable MTLE.

**ACKNOWLEDGMENTS**


**DISCLOSURE OF CONFLICT OF INTEREST**

Author Eric B. Geller, has received support from, and/or has served as a paid consultant for NeuroPace for the RNS System Pivotal trial and as a speaker. Author Tara L. Skarpaas, has received support from, and/or has served as a paid consultant for NeuroPace, including employment and/or equity ownership/stock options. Author Robert E. Gross, has received research support from, and served as a paid consultant to NeuroPace, Inc., and Medtronic, Inc. NeuroPace, Inc., develops products related to the research described in this paper. The terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict of interest policies. Author Robert R. Goodman, has received support from, and/or has served as a paid consultant for NeuroPace. Author Gregory L. Barkley, has received support from the National Institutes of Health for the NIH MONEAD program. Author Kimford J. Meador, has received support from, and/or has served as a paid consultant for the Epilepsy Foundation, and a gift from the American Epilepsy Society. Author Robert E. Gross, has received support from, and/or has served as a paid consultant for Cipla. Author Michel J. Berg, has received support from Upsher-Smith Laboratories, Sunovion, NeuroPace, Lundbeck, Pfizer, King Pharmaceuticals, Sage Therapeutics, and Acorda Therapeutics for industry-sponsored research and is the principal investigator on a study sponsored by the U.S. Food and Drug Administration (FDA; contract HHSF22320111012A), a grant from the Epilepsy Foundation, and a gift from the American Epilepsy Society. Author Gregory Bergey, has received support from Neurotherapeutics in the capacity of Associate Editor. Author Andrew J. Cole, has received support from, and/or has served as a paid consultant for NeuroPace, Sage Therapeutics, and BrainVital/Precisio. Author Nathan B. Fountain, has received support from NeuroPace, Medtronic, UCB, and SK Life Sciences from research grants awarded to these companies. Author Ryder P. Gwinn, has received support from, and/or has served as a paid consultant for Medtronic and NeuroPace, although not during his participation in the RNS System Feasibility or Pivotal trials. Author Aamir A. Herekar, has received support from Sunovion, Eisai, and UCB for serving on their speaker’s bureau. Author Lawrence J. Hirsch, has received support (honoraria) from NeuroPace for speaking via webinar. Author Kimford J. Meador, has received support from the National Institutes of Health and Sunovion Pharmaceuticals for research. The Epilepsy Study Consortium pays Dr. Meador’s university for his research consultant time related to Eisai, UCB Pharmaceuticals, NeuroPace, Novartis, Supernus, Turing Pharmaceuticals, Upsher-Smith Laboratories, UCB Pharma, and Vaxis Pharmaceuticals. Author Eli M. Mizrahi, has received support from NeuroPace, the US Department of Defense, and royalties from McGraw-Hill Medical, Demos Medical Publishing, UpToDate, and Wolters Kluwer Publishers. Author Paul Rutecki, has received support from Veteran Affairs Research and Development and CURE for research. Author Christopher Skidmore, has received support from, and/or has served as a paid consultant for NeuroPace. Author Paul C. Van Ness, has served as a paid consultant for NeuroPace. Author Paul C. Van Ness, has served as a paid consultant for NeuroPace. Author Paul C. Van Ness, has served as a paid consultant for NeuroPace.
received support from NeuroPace during the RNS System Pivotal trial. Author David G. Vossler, receives support from Acorda, Eisai, Marinus, Pfizer, SK Life Science, and UCB Pharmaceuticals for conducting clinical trials and is on the speaker’s bureau and/or advisory boards for Eisai, Lundbeck, Sunovion, and UCB Pharmaceuticals. Author Gregory A. Worrell, has received support from the National Institutes of Health and Medtronic. Author Richard S. Zimmerman, has received support from, and/or has served as a paid consultant for NeuroPace, including employment and equity ownership/stock options. The remaining authors have no conflicts of interest that are relevant to this research activity. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

References


